Odyssey Health (ODYY) Net Income towards Common Stockholders (2014 - 2026)
Odyssey Health (ODYY) posted quarterly Net Income towards Common Stockholders of $765890.0 for Q2 2026, up 404.23% year-over-year from $151891.5 in Q2 2025, and up 228.86% quarter-over-quarter from -$594371.0 in Q1 2026.
Odyssey Health (ODYY) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Odyssey Health's Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at $765890.0 for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 404.23% year-over-year to $765890.0; the TTM figure through Apr 2026 stood at -$478923.0 (up 96.54% YoY), while the FY2025 annual figure was -$1.7 million, down 92.4% from the prior year.
- Net Income towards Common Stockholders for Q2 2026 stood at $765890.0, up from -$594371.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $13.2 million in Q1 2024, with the low at -$12.7 million in Q3 2024.
- The 5-year median for Net Income towards Common Stockholders is -$731108.5 (2023), against an average of -$826890.7.
- Peak annual rise in Net Income towards Common Stockholders reached 890.45% in 2024, while the deepest fall reached 1465.03% in 2024.
- Odyssey Health's Net Income towards Common Stockholders stood at -$2.1 million in 2022, then surged by 74.96% to -$538100.0 in 2023, then decreased by 20.46% to -$648208.0 in 2024, then surged by 38.52% to -$398526.0 in 2025, then soared by 292.18% to $765890.0 in 2026.
- Business Quant data shows ODYY's Net Income towards Common Stockholders at $765890.0 in Q2 2026, -$594371.0 in Q1 2026, and -$398526.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Odyssey Health | 1.01 Mn | 711,880.61 | - | 765,890.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 765,890.00 |
| Jan 31, 2026 | -594,371.00 |
| Oct 31, 2025 | -398,526.00 |
| Jul 31, 2025 | -251,916.00 |
| Apr 30, 2025 | -251,743.00 |
| Jan 31, 2025 | -220,126.00 |
| Oct 31, 2024 | -648,208.00 |
| Jul 31, 2024 | -12.74 Mn |
| Apr 30, 2024 | -842,341.00 |
| Jan 31, 2024 | 13.21 Mn |
| Oct 31, 2023 | -538,100.00 |
| Jul 31, 2023 | -814,009.00 |
| Apr 30, 2023 | -1.28 Mn |
| Jan 31, 2023 | -1.67 Mn |
| Oct 31, 2022 | -2.15 Mn |
| Jul 31, 2022 | -1.18 Mn |
| Apr 30, 2022 | -3.10 Mn |
| Jan 31, 2022 | -2.18 Mn |
| Oct 31, 2021 | -1.65 Mn |
| Jul 31, 2021 | -2.58 Mn |